CN105534936A - Abuse resistant drugs, method of use and method of making - Google Patents

Abuse resistant drugs, method of use and method of making Download PDF

Info

Publication number
CN105534936A
CN105534936A CN201510883951.2A CN201510883951A CN105534936A CN 105534936 A CN105534936 A CN 105534936A CN 201510883951 A CN201510883951 A CN 201510883951A CN 105534936 A CN105534936 A CN 105534936A
Authority
CN
China
Prior art keywords
pharmaceutical composition
hours
medicine
layer
diffusion layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510883951.2A
Other languages
Chinese (zh)
Other versions
CN105534936B (en
Inventor
曼尼诗·S·沙哈
雷·J·迪夫高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insperrun Transportation Science Co ltd
Ohemo Life Sciences Inc
Original Assignee
Inspirion Delivery Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105534936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inspirion Delivery Technologies LLC filed Critical Inspirion Delivery Technologies LLC
Publication of CN105534936A publication Critical patent/CN105534936A/en
Application granted granted Critical
Publication of CN105534936B publication Critical patent/CN105534936B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10Methods of surface bonding and/or assembly therefor

Abstract

The invention relates to an abuse resistant drugs, and a method of use and method of making. An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Description

Abuse resistant drugs, using method and preparation method
The application is application number is 200880103447.4, and the applying date is on August 12nd, 2008, and denomination of invention is the divisional application of the Chinese patent application of " abuse resistant drugs, using method and preparation method ".
This application claims the priority of U.S.Provisional Serial 60/955,584 submitted on August 13rd, 2007, its by reference its entirety be incorporated at this.
Background technology
The present invention relates generally to field of medicinal compositions, and reduce inappropriate drug administration and they indicate or the compositions of probability that the mode of OTC (over-the-counter) uses with non-in particular to being designed for.The present invention can comprise any medicine, the medicine particularly abused.Specifically, it relates to analgesic drug product, alleviates or eliminate the medicine (psychotherapeutic drug) of anxiety attack, beta stimulant and sleeping pill.These universal medicines have the probability of abuse that can cause overdose, addiction, suboptimum effect and/or death.
Especially, the present invention relates to and have, but be not limited to the anti-abuse compositions (such as analgesic drug product, anxiety outbreak medicine, sleeping pill or beta stimulant) on diffusion layer and barrier layer; The purposes of this compositions in the dosage form of disease therapy or illness; And preparation has the method for the compositions of the prevention abuse on diffusion layer and barrier layer.In some embodiments, compositions also comprises extension layer.
OPIOIDS agonist is that described opioid receptor is present in brain, spinal cord and gastrointestinal tract by being incorporated into the specific proteins being called opioid receptor and the material worked.When being incorporated into some opioid receptor in brain and spinal cord when these medicines, they can block the transmission of pain information to brain effectively.Opioid analgesic, such as oxycodone, morphine, oxymorphone, hydrocodone and hydromorphone are successful and the upper useful analgesic drug product for the treatment of.Unfortunately, change emotion due to them and/or cause the ability of excited sensation (" excited "), they also provide the serious threat of abuse arbitrarily.The sustained release forms of this medicine available at present attracts misuser especially, because sustained release effect is by crushing or rolling said preparation and destroy, described sustained release forms contains relatively a large amount of medicines, is intended to discharge from said preparation within a period of time extended.The material (preparation namely crushed) produced no longer controls the release of medicine.According to medicine, misuser then can this material of (1) snuffing, and (2) swallow this material or (3) by this substance dissolves in water or wine, intravenous injection subsequently it.Therefore, the dosage of the medicine contained in preparation is absorbed immediately by nasal mucosa or GI mucosa (respectively for snuffing or swallow), or injects and be applied to systemic circulation (for IV injection).
These abuse methods produce in single tablet or capsule the quick bio availability of the medicine of the relative high dose contained, and make misuser's " excited ".Peak serum concentration (Cmax) height correlation of excited sensation or " excited " and medicine.Although this high plasma concentration can by once taking several rapid releases or continuous release tablet and obtaining, but misuser is prevented from doing like this, because it is more difficult to obtain multiple tablet, and may more importantly, (the high blood plasma level of usual medicine is the function of a period of time extended along with the risk of the serious over administration increased once to take the adjoint very high dosage of several tablets; Produce high area under curve: the integration of Plasma concentrations versus time, be also known as abbreviation " AUC ").In order to reduce the risk of over administration, typical misuser preferably will obtain high peak serum concentration from single tablet or capsule.In the scientific terminology of pharmacologist, typical misuser shows as and makes Cmax maximize and AUC is minimized, or makes Cmax/AUC alternatively than maximizing.
In some instances, misuser drinks and takes rapid release and/or delayed release preparation to reach more rapidly " excited ".Sometimes, preparation is placed in water or wine by misuser, thus extracts medicine with accelerated mode.These liquid known use the time of sometimes reducing and reaching peak serum concentration and Cmax after medicament administration altogether.Sometimes, preparation is placed in other solvents by misuser, such as freon, dichloromethane, ethanol and acetone, thus extracts medicine, then can be injected.Another technology that misuser extracts medicine used from dosage form (such as tablet) wipes the coating of tablet, tablet is pressed into trickle powder, powder is placed in sterilized water, then pour liquid into syringe.In addition, by crushing, rolling and chew and generally physically destroy this dosage form.
Because relatively simple method (crush, roll, chew and/or be dissolved in water or wine) can be used for single delayed-release tablet or capsule preparations to change into and can abuse form, therefore in fact the dosage form of these routines does not provide obstruction to potential misuser.
Due to the report of lasting abuse and transfer, FDA strengthens recently ( ) (controlled release oxycodone hydrochloride) tablet label in warning and preventive measure part, this tablet be approval be used for the treatment of the narcotics of moderate to severe pain. containing oxycodone hydrochloride (usable intensity 10,20,40,80 and 160mg), a kind of OPIOIDS agonist with the addiction probability similar to morphine. with controlled release form supply, and be intended to for moderate to severe pain provides the alleviation reaching 12 hours.FDA warning set forth especially, and this tablet must be taken by full wafer, and by means of only oral.When this tablet is chewed or crushed, and its content is swallowed, snuffing enters nostril or dissolve and intravenous injection subsequently time, controlled release mechanism is destroyed, and the oxycodone of danger dose become can biological utilisation, it may the user of this product lethal, particularly user first.
In recent years, existing many reports that oxycodone is shifted and abused in several state.Such as, the medicine transfer control office of DEA reports 700 examples in the U.S. between June in January, 2000 to calendar year 2001 usurp.Some in the case of these reports create serious consequence, comprise death.
Oxycodone is the control medicine in the list II of controlled substance method (CSA), and this method is implemented by drug enforcement administration (DEA).Although in fact list II provides the maximum that may control of CSA to the medicine of approval, in fact law enforcement agency is difficult to the transfer of legal prescription or the control of misuse.Although abuse, misuse and transfer are the potential problems of all OPIOIDS comprising oxycodone, when suitably using under the careful supervision doctor, OPIOIDS is the very important part of the medical substances of control pain.The current available preparation of this medicine is designed to Orally administered, but does not comprise preventing or hindering and such as chew, inject and the mechanism of unsuitable application process of snuffing.This represents, opens a large amount of legal prescriptions create serious problem in the U.S.; Such as in the U.S., the medical application from 1996 to OPIOIDS in 2000 adds 400%.
The problem of abuse is obvious and long-term, and the effort designing new anti-abuse or anti-abuse preparation is unsuccessful to a great extent.U.S. Patent number 3,980,766 describe and mix Absorbable rod solid, and when its aqueous solution concentrates, it causes increase sharply (gelation) of viscosity.U.S. Patent number 4,070,494 describe to be enough to provide the amount of drug resistance to mix nontoxic water to water extract can the material of gelation, therefore postpones the release of medicine.U.S. Patent number 6,309,668 describe and are used for Orally administered tablet, and it contains two or more layers, and it is included in one or more medicines in each layer of the separation of tablet and one or more gellant.Embodiment in this patent all describes when combining with the water yield needed for dissolved substance, and the tablet of conventional immediate release preparation and generation forms gel; Therefore this one dosage type low temperature reduces medicine from the extraction ratio tablet.Although it should be noted that these compositionss can prevent the abuse by injection, this method can not prevent by crushing and swallow or the abuse of snuffing said preparation, these be with the abuse methods of relevant usual report.
U.S. Patent number 6,277,384,6,375,957 and 6,475,494 describe the peroral dosage form comprising Orally active OPIOIDS agonist and Orally active OPIOIDS antagonist and combine with certain proportion, when oral delivery, this ratio makes it need in the curee looked after to be effectively analgesia but disgusting.Although this preparation successfully can prevent abuse, it also has the probability had side effects in rational patient.
U.S. Patent Application Publication No. 2007/0066537 discloses anti-abuse OPIOIDS, and wherein this OPIOIDS is incorporated into nicotinic acid, biotin or peptide.
U.S. Patent Application Publication No. 2006/0104909 discloses the pharmaceutical composition comprising OPIOIDS and anti-interference substrate, described anti-interference substrate comprises the cross linked polymer of one or more adhesions, and it can be combined with OPIOIDS so that OPIOIDS can not discharge immediately substantially from polymer.Preferred aspect uses water-insoluble host material further, comprise the insensitive material of pH, such as ethyl cellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymer, acrylate/methacrylate copolymer, polyethylene glycol oxide, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, triglyceride, hydrogenated vegetable oil, triglyceride gather the protein of alkoxy alkyl, fat, wax and water-insoluble Partial digestion.Surface coatings material comprises hydrophobic polymer, such as pharmaceutically acceptable acrylate copolymer, such as acrylic acid and methacrylic acid copolymer, methylmethacrylate copolymer, ethoxyethyl methacrylates, methacrylic acid cyanaoethyl methacrylate, Eudragit E100, poly-(acrylic acid), polymethylacrylic acid, methacrylic acid alkylamide copolymer, poly-(methyl methacrylate), poly-(methacrylic anhydride), methyl methacrylate, polymethacrylates, polyvinyl lactam and glycidyl methacrylate copolymer.In certain preferred aspects, acrylate copolymer is made up of one or more ammonium methacrylate ester copolymers.Ammonium methacrylate ester copolymer is well known in the art, and in NFXVII, be described as the acrylic acid of the quaternary ammonium group with low content and the copolymer be polymerized completely of methacrylic acid.
U.S. Patent Application Publication No. 2005/0281748 discloses and OPIOIDS is incorporated into lipid or fatty acid to produce abuse resistant drugs.
The object of this invention is to provide a kind of pharmaceutical composition, it significantly reduces the unsuitable probability used or use of medicine, but when using as shown, can the effective dosage of delivery treatments.Especially, the present invention caters to the demand to a kind of medicine, and described medicine and conventional formulation contrast, and reduces with unsuitable intensity, degree, frequency and the speed of using the appearance occurring " excitement " effect.
Summary of the invention
The present invention relates to a kind of anti-abuse combination of oral medication, it comprises: the barrier layer comprising the first polymer; With the diffusion layer comprising the second polymer covering barrier layer substantially, wherein diffusion layer is incorporated into barrier layer, and comprises and to be evenly distributed in very much in the second polymer and from the medicine of diffusion layer diffusion in gastrointestinal (GI) road.Described pharmaceutical composition optionally comprises extension layer, and it comprises easily extensible polymer, and wherein extension layer is covered substantially by barrier layer.
The invention still further relates to a kind of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein pharmaceutical composition is formulated, so that when pharmaceutical composition is applied to curee with physically destroyed form, in a period of time, medicine is equal to or less than drug release rate when pharmaceutical composition is used with complete form substantially from the speed that compositions discharges, and described a period of time is selected from by 2 hours, 4 hours, 8 hours and the group that forms for 16 hours.
The invention still further relates to a kind of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein pharmaceutical composition is formulated, so that when pharmaceutical composition is applied to curee with physically destroyed form, the amount that in a period of time, medicine discharges from compositions, substantially identical or lower compared to the amount of the drug release when pharmaceutical composition is used with complete form, preferably lower than 20%, more preferably less than 30%, and most preferably lower than 40%, described a period of time is selected from by 2 hours, 4 hours, 8 hours and the group that forms for 16 hours.In the context of this application, phrase " substantially identical " refers in (+/-) 30%, preferably in (+/-) 20%, and more preferably in (+/-) 10%.
The invention still further relates to a kind of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein pharmaceutical composition is formulated, so that when pharmaceutical composition thereof wine or when taking together with wine, the speed that in a period of time, medicine discharges from compositions, substantially identical or lower compared to the speed of the drug release when pharmaceutical composition is not used together with wine, preferably lower than 40%, more preferably less than 30%, and most preferably lower than 20%, described a period of time is selected from by 2 hours, 4 hours, 8 hours and the group that forms for 16 hours.
The invention still further relates to a kind of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein pharmaceutical composition is formulated, so that when pharmaceutical composition is used with complete form, after 8 hours, the medicine of the amount of at least 50% is released, and when pharmaceutical composition is used with physically destroyed form, after 1 hour, be no more than 40%, the medicine preferably more than the amount of 30% is released.
The invention still further relates to a kind of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein pharmaceutical composition is formulated, so that when pharmaceutical composition is used with complete form, after 1 hour, the medicine of the amount of at least 90% is released, and when pharmaceutical composition is used with physically destroyed form, after 1 hour, the medicine being no more than the amount of 75% is released.
The invention still further relates to a kind of method preparing anti-abuse combination of oral medication, it comprises: form barrier layer, wherein barrier layer comprises the first polymer; And diffusion layer is applied to basic covering barrier layer on barrier layer, wherein diffusion layer comprises the second polymer and is evenly distributed on the medicine in the second polymer; And diffusion layer is incorporated into barrier layer preferably by physical bond.
The invention still further relates to a kind of method preparing anti-abuse combination of oral medication, it comprises: form extension layer, it comprises easily extensible polymer; And by barrier application on extension layer substantially to cover extension layer, wherein barrier layer comprises the first polymer; And diffusion layer is applied to basic covering barrier layer on barrier layer, wherein diffusion layer comprises the second polymer and is evenly distributed on the medicine in the second polymer; And diffusion layer is incorporated into barrier layer preferably by physical bond.In some embodiments, barrier layer is applied on extension layer by spraying or dry coating.
The invention still further relates to a kind of method for the treatment of illness, it comprises uses pharmaceutical composition of the present invention to its patient of needs.
The invention still further relates to a kind of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein pharmaceutical composition is formulated, so that when pharmaceutical composition is applied to curee with physically destroyed form, the intensity of the excitement that excited intensity realizes after being substantially equal to or less than the physically destroyed bioequivalent compositions of the method used not containing anti-abuse.
Accompanying drawing explanation
Fig. 1 contrasts suitably percentage ratio rate of release and the figure of time that (complete) takes the tablet prepared according to embodiment 31 and the same piece agent formulation taking ground form.For anti-abuse oxycodone tablet (preferred embodiment), at deionized water; 100RPM; Basket method; Comparison in-vitro release rate in 900mL, intact tablet is compared to the tablet ground.
Fig. 2 is contrast the tablet ground and the percentage ratio rate of release of the tablet ground of preparation of embodiment 31 and the figure of time.For anti-abuse oxycodone tablet (preferred embodiment), at deionized water; 100RPM; Basket method; Comparison in-vitro release rate in 900mL, OxyContin RTM is compared to anti-abuse oxycodone tablet.
Fig. 3 be the display feature of the present invention utilizing Microsoft Excel Software program to obtain body in simulation drawing.As grind tablet and snuffing subsequently mill pulverized powder after as shown in, rapid release commercially available at present or the tablet of delayed release will show Cmax-1.Identical tablet, when complete picked-up, will be shown as Cmax-2, because the speed absorbed postpones because of the physiologic factor in gastrointestinal tract.Bioequivalence tablet formulation of the present invention is by feature identical with Cmax-2 curve for display.But tablet of the present invention, when grinding also snuffing, will be shown as lower Cmax-3.
Fig. 4 be contrast suitably (complete) take according to embodiment 31 prepare tablet and take " incision form " same piece agent formulation percentage ratio rate of release and the figure of time.For anti-abuse oxycodone tablet (preferred embodiment), at deionized water; 100RPM; Basket method; Comparison in-vitro release rate in 900mL.
Detailed description of the invention
Abuse resistant drugs compositions of the present invention concept behind provides the medicine of necessary amount to realize pharmacy effect (such as pain relief) to patient, and reduce potential misuser and transform compositions thus stand " excited ", or the ability of induction quick death.Usually abused, and be therefore suitable for medicine of the present invention particularly including analgesic drug product (such as OPIOIDS), anxiety outbreak medicine, sleeping pill and beta stimulant.
Anti-abuse compositions of the present invention is being destroyed when the physical integrity of dosage form containing said composition, and the preparation produced subsequently by snuffing, inject or swallow time, can postpone or at least not significantly increasing medicament from the release of dosage form.Compositions, when it exists with the form outside complete form, is " being physically destroyed ".This is by accomplished in many ways, and such as by chewing, mince, grind, crush or being placed in solvent, described solvent such as contains those solvents and/or the water of alcohol (such as ethanol).Therefore, compositions of the present invention provides obstruction to the unsuitable common methods used, because medicine can not from preparation immediately and promptly discharge, and because with complete formulations Comparative, the actual amount of drug release may be lowered, wherein saidly unsuitablely use the intravenous injection comprising the medicine being dissolved in solvent, and the nose of the preparation crushed is used or Orally administered.When by indicated using, medicine, in gastrointestinal (GI) road, discharges from compositions more step by step preferably by dissolving and/or flooding mechanism.
According to an embodiment, abuse resistant drugs compositions of the present invention comprises: the barrier layer comprising the first polymer; With the diffusion layer comprising the second polymer covering barrier layer substantially, wherein diffusion layer is incorporated into barrier layer, and comprises and to be evenly distributed in very much in the second polymer and in the gastrointestinal tract from the medicine of diffusion layer diffusion.Described pharmaceutical composition optionally comprises extension layer, and it comprises easily extensible polymer.Pharmaceutical composition comprises in the embodiment of extension layer wherein, and barrier layer covers extension layer substantially.
Anti-abuse compositions of the present invention can comprise be designed for Orally administered arbitrary delayed release preparation and quick releasing formulation or both, described delayed release preparation has slow releasing in the typical body of medicine within the time of about 6 to about 24 hours or external, preferably the medicine of at least 80% was release in about 12 to about 24 hours, described quick releasing formulation has preferably at least 80%, more preferably at least 90%, and most preferably the medicine of at least 95% discharged in 1 hour.
Anti-abuse combination of oral medication can be any pharmaceutical dosage form, includes but not limited to tablet, capsule, microplate, granule, pill, lollipop, lozenge and coated capsule.In preferred embodiments, anti-abuse combination of oral medication is Tabules.
Anti-abuse combination of oral medication comprises in the embodiment of optional extension layer wherein, and extension layer is the innermost layer in three layers of pharmaceutical composition.Extension layer is preferably inert layer, and it is not containing any medicine, and it comprises easily extensible polymer.Extension layer preferably has about 0.5 to 15mm, more preferably from about 2 to 12mm, and the thickness of most preferably from about 4 to 10mm.The thickness of extension layer is preferably about 5% to 95% of tablet thickness, and more preferably from about 40% to 95%, and most preferably from about 50% to 90%.
In some embodiments, when the easily extensible polymer of optional extension layer is exposed to liquid, when preferably including the liquid of water and/or alcohol (such as ethanol), easily extensible Polymer absorption liquid, and preferably expand and/or form gel.Preferred hydrophilic polymer, the hydrophilic polymer most preferably expanded when contact liq and/or gel.In a preferred form, when extension layer in anti-abuse compositions by physical damage, and formed containing extension layer compositions fragment after, when being exposed to liquid, easily extensible polymer at least absorbs a part of liquid and forms gel.Gel preferably postpones the release of medicine from diffusion layer further.In addition, the viscosity of increase can make misuser be difficult to preparation to pour into syringe to be used for injection.Extension layer preferably includes the polymer existed with the weight range of 5% to 90% of the gross weight of dosage form.
The typical agent used in extension layer includes but not limited to methylcellulose, sodium carboxymethyl cellulose, methyl hydroxyethylcellulose, methylhydroxypropylcellulose, alginic acid, polyacrylic acid and tragacanth, or the combination of two or more in these materials.Most preferably hydroxypropyl emthylcellulose and polyacrylic acid, hydroxypropyl emthylcellulose is sometimes with trade (brand) name sell, and polyacrylic acid is sometimes with trade (brand) name sell.
Extension layer also can comprise disintegrating agent, such as cross-linking sodium carboxymethyl cellulose or Explotab, with auxiliary guarantee extension layer rapid dispersion in liquid.The added ingredient that can be present in extension layer includes but not limited to filler, dyestuff, lubricant or water permeation promoter, such as sodium chloride.High soluble polymer, disintegrating agent or its be combined in pharmaceutical field and widely known, and as skilled in the art to understand, any suitable high soluble polymer or disintegrating agent or equivalent material can with the present invention and embodiment conbined usage thereof.
Barrier layer is in the inside of diffusion layer.Some wherein pharmaceutical composition comprise in the embodiment of extension layer, extension layer is the innermost layer in three layers, and barrier layer covers extension layer substantially.The basic covering of extension layer refers to more than 80%, more preferably above 90% and the extension layer of override more than 95% is covered by barrier layer.The covering of 100% is most suitable.
Barrier layer preferably has about 0.1 to 2.5mm, more preferably from about 0.2 to 2.0mm, and the thickness of most preferably from about 0.5 to 1.5mm.The thickness on barrier layer is preferably about 5% to 50% of the gross thickness of compositions, and more preferably from about 8% to 30%, and most preferably from about 10% to 25%.
Barrier layer has many functions.Such as, barrier layer is used as the barrier between diffusion layer and extension layer, reduces when dosage form exists with complete form, can enter the amount of the liquid of extension layer.In addition, barrier layer is for improving the mechanical strength of compositions.
Barrier layer comprises polymer.Typical barrier polymers includes but not limited to that polyacrylate and copolymer thereof are (such as with trade (brand) name nE30D sell those), fS30D, rS30D, from 's from 's and nE30D and mixture, Polyethylene Glycol, polyethylene glycol oxide, polyethylene, polypropylene, polrvinyl chloride, Merlon, polystyrene and similar polymer.The preferred polymers on barrier layer is polyacrylate and Polyethylene Glycol, and particularly polyacrylate dispersion.Pharmaceutical composition comprises in the embodiment of extension layer wherein, and barrier layer also can be bonded in extension layer containing binding agent with auxiliary its.The use of the polymer of antibiont degraded, binding agent or its combination is widely known in pharmaceutical field, and as skilled in the art to understand, any suitable antibiont polymer or adhesion promoter can with the present invention and embodiment conbined usage thereof.
Preferably, when the dosage form containing anti-Drug abuse compositions of the present invention is applied to curee with complete form, barrier polymers is not dissolved substantially in gastrointestinal tract, mucosa, blood vessel or lung.In addition, health is passed with largely insoluble form in barrier layer." substantially insoluble " refers to be less than 30%, is more preferably less than 20%, and the polymer being most preferably less than 10% is dissolved.
The basic covering barrier layer of diffusion layer.The basic covering on barrier layer refers to more than 80%, more preferably above 90%, and is covered by barrier layer most preferably more than the extension layer of 95%.The covering of 100% is most preferred.
Diffusion layer comprises polymer and medicine, is preferably substantially evenly distributed in the medicine in polymer." distributing substantially equably " refers to more than 80%, more preferably above 90%, and is equally distributed most preferably more than the medicine of 95%.The polymer of diffusion layer and pharmaceutical dispersions are employed and are incorporated into barrier layer.
Diffusion layer is preferably a thin layer, and it has the large surface area compared with the thickness of this layer.Diffusion layer preferably has about 0.1 to 1.0mm, more preferably from about 0.15 to 0.7mm, and the thickness of most preferably from about 0.2 to 0.4mm.The thickness of diffusion layer is preferably about 1% to 30% of tablet thickness, and more preferably from about 2% to 20%, and most preferably from about 3% to 10%.In a preferred embodiment of the invention, compared with the surface area of diffusion layer, diffusion layer is relative thin.
In some preferred embodiments, one or more containing dyestuff in each layer, when with liquid or saliva contacts, generations is dyeed or color by it.This can assist the anti-abuse feature of tablet of the present invention.The example of dyestuff includes but not limited to FD & CRed#3, FD & CRed#28 and FD & CBlue#1.
The medicine mixing pharmaceutical composition of the present invention can be any medicine, or any compositions of two or more medicines.But usually, one or more medicines will be often by the medicine abused, such as central nervous system stimulant and depressant.The example of central nervous system stimulant includes but not limited to amphetamine, and the agent of such as cocaine.The example of central nervous depressant includes but not limited to OPIOIDS class, barbiturates, Benzodiazepines and other antianxiety drugss and sleeping pill.The example of the compositions of two kinds of medicines comprises oxycodone and morphine.
The example of OPIOIDS includes but not limited to following: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, Clonitazene, codeine, Desomorphine, dextromoramide, dezocine, diampromide, diamorphine, dihydrocodeine, paramorphan (dihydromorphine), dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, Pethidine, meptazinol, metazocine, methadone, metopon, morphine, Myrophine, papaverine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, pirinitramide, propheptazine, Promedol, properidine, dextropropoxyphene, sufentanil, tilidate and tramadol.Any OPIOIDS or its pharmaceutically acceptable salt or ester can be used for anti-abuse compositions.Preferred OPIOIDS comprises fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, morphine, hydroxycodone, dextropropoxyphene, pentazocine, methadone, tilidate, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, Pethidine and dihydrocodeinone.Preferred OPIOIDS comprises oxycodone, hydrocodone, codeine, morphine, oxymorphone and hydromorphone, and its pharmaceutically acceptable salt and ester.The most particularly preferred OPIOIDS is oxycodone and morphine, and pharmaceutically acceptable salt.
The example of barbiturates includes but not limited to enphenemal, and (it is sometimes with trade (brand) name sell) and pentobarbital sodium (it is sometimes with trade (brand) name sell).Usually the prescription of barbiturates is opened to treat anxiety, anxiety and sleep disorder.
The example of Benzodiazepines and Benzodiazepine derivant includes but not limited to that diazepam is (sometimes with trade (brand) name sell), alprazolam is (sometimes with trade (brand) name sell), triazolam ( ) and estazolam ( ).Usually Benzodiazepines prescription is outputed to treat anxiety, gross stress reaction and panic attack.
The example of another CNS inhibitor is Zaleplon, and it is sometimes with trade (brand) name sell.
Although various types of CNS inhibitor works by different way, they can produce useful hypnosis or sedation in the individuality of illness suffering from such as sleep disorder and anxiety.But if these medicines of people's life-time service, its health can produce toleration, and larger dosage may be needed to realize initial effect.In addition, continuous print uses can cause physical dependence, and when minimizing or when stopping using, produces withdrawal symptom.Barbiturates and Benzodiazepines both have the probability of abuse, and should only use according to prescription.As OPIOIDS, the over administration of these medicines may be fatal.
Beta stimulant increases heart rate, blood pressure and metabolism, sometimes produces the happy and sensation of spirit and the alertness of raising.Usually open amphetamine-type such as methylphenidate (sometimes with trade (brand) name sell) and dexamphetamine (sometimes with trade (brand) name with sell) prescription be used for the treatment of narcolepsy, attention-deficient/hyperactivity disorder, and do not respond the depression of other treatment.They are also used to the short term therapy of obesity.The individual energy addiction that can become sensation to the producible happiness of beta stimulant and enhancing.But the beta stimulant repeatedly taking high dose in the short time can produce hostility or paranoea.In addition, the beta stimulant taking high dose can produce jeopardously high fever and irregular heart beating.
The preferred embodiments of the invention comprise following medicine and amount: oxycodone or its pharmaceutically acceptable salt, and it exists with the amount of about 5mg to about 400mg; Morphine or its pharmaceutically acceptable salt, it exists with the amount of about 15mg to about 800mg; Hydromorphone or its pharmaceutically acceptable salt, it exists with the amount of about 1mg to about 64mg; Hydrocodone or its pharmaceutically acceptable salt, it exists with the amount of about 5mg to about 400mg; And oxymorphone or its pharmaceutically acceptable salt, it exists with the amount of about 4mg to about 80mg.
Except one or more medicines, diffusion layer contains one or more polymer.The example that can be used for the polymer of diffusion layer includes but not limited to, ethyl cellulose, quaternary ammonium acrylic or methacrylate polymer, acrylic or methacrylic acid ester copolymer or its mixture, it also can be used as sustained release agent.Common trade (brand) name comprises multiple grade (all from ) and (from ).The preferred polymers of diffusion layer is acrylic or methacrylic acid polymer, and particularly ethyl acrylate or methyl methacrylate dispersion.Polymer dispersion, the use of the polymer particularly worn and torn gradually is widely known in pharmaceutical field, and as skilled in the art to understand, any suitable polymer worn and torn gradually can with the present invention and embodiment conbined usage thereof.
Suitable wax can replace part or all of polymer in diffusion layer.Suitable wax comprises synthetic wax and native paraffin, and ceroidlike material, fat and lipid, hydro carbons (such as paraffin, Cera Flava, Brazil wax and similar substance), comprise the compositions of these materials.These materials dissolve slowly or completely insoluble in the gastrointestinal tract.The use of ceroidlike material is widely known in pharmaceutical field, and as skilled in the art to understand, any suitable ceroidlike material can with the present invention and embodiment conbined usage thereof.
Diffusion layer is also optionally containing continuing or delayed release and/or enteric coating.The example of this material is cellulose acetate phthalate, Hydroxypropyl Methylcellulose Phathalate, poly-phthalic acid acetic acid ethylene, methacrylic acid: acrylate copolymer, HPMCAS, lac, trimellitic acid cellulose acetate and composition thereof.Diffusion layer also can contain water-soluble polymer, such as polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, has from 1,700 to 20, the Polyethylene Glycol of the molecular weight of 000 and polyvinyl alcohol and monomer whose, and its mixture.The use continuing the material of coating, prolongation coating and enteric coating is widely known in pharmaceutical field, and as skilled in the art to understand, any suitable lasting coating, the material extending coating and enteric coating or similar agent can with the present invention and embodiment conbined usage thereof.
In preferred embodiments, for barrier layer and diffusion layer, acrylic acid coating be with aqueous dispersion use acrylic paint, its purchased from pharma, trade mark is called
Medicine distributing substantially equably in the polymer of diffusion layer such as makes medicine discharge in the gastrointestinal tract with the desired rate determined, so that it discharges medicine lentamente.Diffusion layer can be immediate release layer or delayed release layer.Diffusion layer, preferably in reaching 24 hours, preferably maintains the release characteristic identical with conventional complete formutatibh, even when this layer is broken into smaller pieces.The existence of medicine in diffusion layer is considered to cause forming hole in the polymer of diffusion layer.The existence in hole makes diffusion layer wear and tear gradually, and drug release.The rate of release of medicine regulates by the size changing polymer orifices.The minimizing of the size of such as polymer orifices can reduce the rate of release of medicine.Diffusion layer is stretched or is exposed to solvent also will to reduce the size of polymer orifices, and reduce the rate of release of medicine.
Diffusion layer and barrier layer be combined with each other.Each layer is by any methods combining as known in the art.In some embodiments, each layer is chemically combined, or preferably, they are physically combined.In preferred embodiments, secondary or physical bond is formed between the layers by heat setting.In another preferred embodiment, each layer exists in powder form, and by using tablet machine physically to combine.In some embodiments, extension layer and group barrier layer can be prepared into bolus, and store a period of time, preferably reach seven days, as long as barrier layer is not eliminated.
Preferably, compositions formulated is consequently when pharmaceutical composition is physically damaged, and when the granule containing the pharmaceutical composition on diffusion layer and barrier layer is formed, the key in granule between diffusion layer and barrier layer is retained substantially.In a preferred embodiment of the present invention, destroy pharmaceutical product by this way and will cause diffusion synusia with stop synusia because destructive activity closely combines in granule.Therefore, in a preferred embodiment of the present invention, when producing granule with 500 order to 8 object scopes, the relative surface area of diffusion layer only will increase (be such as no more than 50%, preferably more than 25%, be most preferably not exceeding 10%) at edge.In a preferred embodiment of the present invention, the control of drug diffusion surface area, or even time destroyed, prevent medicine from discharging fast from medicine composition.
Being formed in of key between diffusion layer and barrier layer realizes in anti-abuse being important, because when dosage form of the present invention is by physical damage, the inner side of barrier layer protected diffusion layer, prevents the remarkable increase of drug release.Therefore, medicine maintains and substantially discharges gradually from the outside of diffusion layer with the speed of its design.
They by applying diffusion layer immediately after application barrier layer in conjunction with design feature, then together process and optimize by layer.
Diffusion layer polymer can drug loading wherein, and therefore after dosage form changes, prevents from medicine from inclining.Barrier layer and optional extension layer strengthen the anti-abuse feature of pharmaceutical composition.
Other component can join any one in each layer or all, condition is their not interference medicaments, and provides required benefit to medicine.Other the example of component this is: the plasticizer used in a known way, antiplastering aid, inert filler, lipophilic agent and pigment.The cohesiveness of the dispersible film substrate of water is by mixing coating simply to overcome by antiplastering aid.The example of antiplastering aid be metallic stearate, microcrystalline Cellulose, calcium phosphate, 200 and Talcum.Those skilled in the art will appreciate that the needs of other components this and apply the problem that it overcomes production, storage period or release characteristic.
The example of plasticizer used according to the invention comprises glyceryl triacetate, acetylated monoglyceride, olive oil, citroflex A-4, CitroflexA-2, glycerol, sorbitol, Polyethylene Glycol and polypropylene glycol.
Filler/diluent/binding agent can be mixed, the lactose of such as sucrose, sorbitol, mannitol, various grade, the microcrystalline Cellulose of various grade, dextrin, maltodextrin, starch or modified starch, sodium phosphate, calcium phosphate, calcium carbonate, gelatin, polyvinylpyrrolidone and sodium carboxymethyl cellulose.
Can disintegrating agent be used, such as cellulose derivative, comprise microcrystalline Cellulose, the hydroxypropyl cellulose of low replacement, cross-linked carboxymethyl cellulose sodium, alginic acid, insoluble polyvinylpyrrolidone and carboxymethyl starch sodium.
Fluidizer and lubricant can be mixed, such as stearic acid, metallic stearate, Talcum, wax and there is the glyceride of high melting temperature, silica sol, sodium stearyl fumarate, Polyethylene Glycol and alkyl sodium sulfate ester.
Surfactant can be used, such as non-ionic surface active agent (Polysorbate of various grade); Anion surfactant, such as docusate sodium and sodium lauryl sulphate, and cationic surfactant, such as benzalkonium chloride.The example of amphoteric surfactant is 1,2-diacyl-L-phosphatidylcholine.Preferred surfactant is and Nanoxyl-100.
Other suitable pharmaceutically acceptable excipient can comprise and do coloring agent, flavoring agent, pH adjusting agent, stabilizing agent, wetting agent, resistant to dissolution agent and buffer agent.
Other layers one or more can be placed under extension layer, or between extension layer and barrier layer, or above diffusion layer or top.Such as, in some embodiments, extension layer does not directly contact barrier layer, because one or more layer can between extension layer and barrier layer.In other embodiments, extension layer can cover another layer be positioned under extension layer.In some embodiments, other the releasing layers one or more comprising one or more other drugs can be positioned at the top of diffusion layer.In some embodiments, other releasing layer can be delayed release layer or release layer.In some embodiments, delayed release layer and release layer all can be positioned at the top of diffusion layer.One or more other drugs can be any medicines, comprise the medicine of a part for the diffusion layer that may be compositions, such as central nervous stimulant and inhibitor, such as OPIOIDS, barbiturates, Benzodiazepines and amphetamine-type.Preferably, be release layer at the layer at the top of diffusion layer, and the medicine in release layer include but not limited to acetaminophen and NSAID (non-steroidal anti-inflammatory drug).
Due to feature described above, the abuse potential of pharmaceutical composition of the present invention is lowered.In addition, in some embodiments, described feature can prevent patient dosage form to be cut into the small pieces of a part of dosage containing intact tablet.Such as, attempt the patient of 80mg tablet being cut into 4 20mg tablet, by the 20mg tablet of cutting compared with unbroken 20mg tablet, required curative effect can not be realized.Be exactly this situation, because in this embodiment of the present invention, the 20mg tablet of incision can not be released in the medicine of the whole 20mg amounts in tablet.
Preferably, when suitably using with complete form, medicine discharges from diffusion layer with required rate of release, and the residue of pharmaceutical composition is with the health of inertia form by patient, because barrier layer prevents the residue of compositions to be destroyed in the gastrointestinal tract.Required rate of release can be usually available from the rate of release of desired use, is such as described in the prescription information relevant to business medicine.
Compositions comprises in the of the present invention preferred embodiment of extension layer wherein, the medicine of physical damage causes extension layer distributing containing between diffusion layer and the granule of thin barrier layer component, become the component of the granule containing diffusion layer and thin barrier layer component, or more two kinds of situations.Therefore, in a preferred embodiment of the present invention, once be exposed to body fluid or other liquid, granule containing diffusion layer and thin barrier layer component embeds the extension layer expanded, so that medicine occurs to the quiet diffusion of body fluid or other liquid with substantially low than the speed diffusing out not destroyed medicine speed.
In a preferred embodiment of the present invention, the pharmaceutical composition produced controls having and maintains the mechanism of medicine from the speed of the drug diffusion of the part containing compositions to a great extent, and once compositions is destroyed, or when being exposed to liquid whole or in part, postpone the drug diffusion of medicine from the part containing compositions, and retain these two kinds of mechanism of mechanism of the basic ratio of medicine.Benefit of the present invention is, is intended to anyone destructive activity that will be difficult to by some types of Drug abuse, so from medicine rapid extraction medicine, and snuffing, swallow or inject.As a result, contrast with conventional formulation, use intensity and quality that the present invention produces the excitement of reduction inadequately, and reduce the excited ratio occurred.Therefore, wish by using this compositions can not realize required " excited " or excitement to reach " excited " or to stand excited misuser inadequately.In addition, less tonic effect, if had, realizes with low-down ratio.Except non-usage complexity with extracting method consuming time, otherwise by application the present invention, the main component of medicine will be sealed, and can not be separated from the medicine of the destruction produced, therefore reduce when snuffing, swallow or inject time total bioavailability.
In preferred embodiments, when this compositions is destroyed, contrast with complete unbroken compositions, discharge the percentage ratio substantially equaled lower than medicine.In preferred embodiments, within a period of time of the group be selected from 2 hours, 4 hours, 8 hours and form for 16 hours, contrast with complete unbroken tablet, within the mutually commensurability time, the compositions release destroyed is no more than 90%, more preferably no more than 75%, and more preferably no more than 60% medicine.
By in conventional manner body and analyzed in vitro technology, in such as body, blood plasma is measured or external drug dissolution, can measure mechanism described above and benefit.Use these technology, the medicine release in time existed in pharmaceutical composition can be monitored, and be expressed as the release percentage ratio of the medicine being present in this compositions at first.In a preferred embodiment of the present invention, when use pharmaceutical composition of the present invention is by physical damage, when then testing in Dissolution Rate Testing in vitro, the percentage ratio of the medicine of release will be quite low.
In the release characteristic of the product of the present invention discussed, the dosage form including the medicine of effective amount has by the USP slurry processes of American Pharmacopeia, use USP equipment I, with 100rpm (basket method) in the 900mL water buffer of pH1.6 and 7.2, the dissolution rate in vitro measured at 37 DEG C.
Preferably, release in vitro is the medicine discharging about 5% to about 50% (by weight) after 1h, discharge the medicine of about 20% to about 65% (by weight) after 4 hours, discharge the medicine of about 35% to about 85% (by weight) after 8 hours, and discharged the medicine of more than 60% (by weight) after 16 hours; More preferably after 1 hour after about 5% to about 40%, 4 hour about 15% to about 60%; After 8 hours about 40% to about 80%; And after 16 hours about 50% to about 90%; More preferably after 1 hour after about 10% to about 35%, 4 hour about 15% to about 55%; After 8 hours about 35% to about 75%; And after 16 hours about 50% to about 80%; Most preferably after 1 hour after about 10% to about 30%, 4 hour about 25% to about 60%; After 8 hours about 40% to about 80%; And after 16 hours about 55% to about 75%.By being often used in the dynamic (dynamical) conventional pharmacokinetic technology of drug characterization in human patients or other mammals, also mechanism described above and benefit can be measured.
The maximally related pharmacokinetic parameter understanding characteristic sum benefit of the present invention is Cmax (maximal plasma concentration of medicine and/or active metabolite) and AUC (under blood plasma concentration curve area: the integration of the Plasma concentrations versus time of medicine and/or active metabolite).In a preferred embodiment of the present invention, when pharmaceutical composition is applied to curee with physically destroyed form, be selected from use after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours with a period of time of the group of 48 hours compositions after Cmax and/or AUC that realize with when identical with Cmax and/or AUC realized during complete form drug administration compositions, or lower than it, preferably about 20-75% lower than it.
One embodiment of the invention relate to compounding pharmaceutical compositions, so that when pharmaceutical composition is applied to curee with physically destroyed form, be selected from use after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours and 48 hours compositions group a period of time after Cmax and/or AUC that produce of the medicine of destruction that realizes, lower than Cmax and/or AUC not using the bioequivalence compositions of the physical damage of the equivalent of anti-abuse methods to produce, preferably low about 20-75%." bioequivalence " pharmaceutical composition refers to containing identical medicine, and has the close set compound of AUC and Cmax of scope in 80% to 125% of AUC and Cmax with reference to pharmaceutical composition.
Another embodiment of the present invention relates to compounding pharmaceutical compositions, so that when pharmaceutical composition is applied to curee with physically destroyed form, be selected from use after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours and 48 hours compositions group a period of time after the Cmax/AUC ratio that produces of the medicine of destruction that realizes, by the Cmax/AUC ratio that the bioequivalence medicine being the physical damage not containing anti-abuse methods produces, or lower than it, preferably low 20-75%.
Another preferred embodiment of the present invention is combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein compounding pharmaceutical compositions, so that when pharmaceutical composition is used with complete form, at least 50%, preferably the medicine of amount of at least 60% discharges after 8 hours, and when pharmaceutical composition is used with physically destroyed form, be no more than 40%, preferably more than 35%, more preferably no more than 30%, and the medicine being most preferably not exceeding the amount of 25% discharges after 1h.Preferably, when pharmaceutical composition is used with physically destroyed form, be no more than 35%, more preferably no more than 30%, and the medicine being most preferably not exceeding the amount of 25% discharged in 15 minutes.
Another preferred embodiment of the present invention is combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein compounding pharmaceutical compositions, so that when pharmaceutical composition is used with complete form, the medicine of the amount of at least 90% discharges after 1h, and when pharmaceutical composition is used with physically destroyed form, be no more than 75%, the medicine preferably more than the amount of 60% discharges after 1h.
The invention still further relates to combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein compounding pharmaceutical compositions, so that when pharmaceutical composition is applied to curee with physically destroyed form, excited intensity be substantially equal to or less than use do not comprise the bioequivalence compositions be physically destroyed of anti-abuse methods after the intensity of excitement that realizes.Excitement is a kind of excited or extremely surging sensation, and it is used after the pharmaceutical composition containing medicine for central nervous system through going through through the misuser that is everlasting.Excited amount or intensity can be measured in a number of different manners.Measure excited method or technology sometimes with other illness of measurement, the method for such as pain or technology type are seemingly.Such as, excited amount or intensity can numeral or lineal scale be measured, and can to standing the amount of excitement of excited people or quantification of intensities or deciding grade and level.Such as, in some embodiments, can 0 to 10 scale measure excited amount or intensity, wherein excited a large amount is appointed as numeral 10, and is not excitedly appointed as numeral 0.Similarly, in some embodiments, measure excited amount or intensity with lineal scale, one end representative of its cathetus is not excited, and the other end of straight line represents the excitement of a large amount.In some embodiments, compounding pharmaceutical compositions, so that when pharmaceutical composition is applied to curee with physically destroyed form, excited intensity is substantially identical with the intensity used not containing the excitement realized after the physically destroyed bioequivalence compositions of anti-abuse methods, or effective selection of land lower than it is less than 10%, be more preferably less than 30%, and be more preferably less than 50%.
The release characteristic of pharmaceutical composition of the present invention preferably depends on pH.In addition, when the USP basket method by American Pharmacopeia, use USP equipment I, with 100rpm (basket method) in the water buffer of 900mLpH1.6 and 7.2, and when measuring at 37 DEG C, preferably at 40 DEG C, after storing 3 months under the relative humidity of 75%, the rate of release of preparation is without significant change (preferably, being less than the change of 10%).
All references cited herein by reference its entirety is incorporated at this.
Use following embodiment to confirm and the present invention is described.
Embodiment 1
Mannitol-90mg
Microcrystalline Cellulose-50mg
71G-128mg
Hydroxypropyl emthylcellulose, 2910 type-128mg
(METHOCEL TMK4MCR)
Magnesium stearate-4mg
Method: mannitol, microcrystalline Cellulose, 71G and METHOCEL tMk4MCR is sieved through #20 order, and mixes 10 minutes in a mixer.Magnesium stearate is sieved through #40 order, and joins blender, and mixes 5 minutes with lubrication mixture.Final mixture is pressed into 400-mg tablet weight, and the hardness between 8-15kp.
Embodiment 2
Mannitol-22.5mg
Microcrystalline Cellulose-12.5mg
71G-32mg
Hydroxypropyl emthylcellulose, 2910 type-32mg
(METHOCEL TMK4MCR)
Magnesium stearate-1mg
Method: mannitol, microcrystalline Cellulose, 71G and METHOCEL tMk4MCR is sieved through #20 order, and mixes 10 minutes in a mixer.Magnesium stearate is sieved through #40 order, and joins blender, and mixes 5 minutes with lubrication mixture.Final mixture is pressed into 100-mg tablet weight, and the hardness between 4-9kp.
Embodiment 3
Mannitol-135mg
Microcrystalline Cellulose-75mg
71G-192mg
Hydroxypropyl emthylcellulose, 2910 type-192mg (METHOCEL tMk4MCR)
Magnesium stearate-6mg
Method: mannitol, microcrystalline Cellulose, 71G and METHOCEL tMk4MCR is sieved through #20 order, and mixes 10 minutes in a mixer.Magnesium stearate is sieved through #40 order, and joins blender, and mixes 5 minutes with lubrication mixture.Final mixture is pressed into 600-mg tablet weight, and the hardness between 8-15kp.
Embodiment 4
Mannitol-70mg
Microcrystalline Cellulose-50mg
CARBOPOL TM71G-128mg
Hydroxypropyl emthylcellulose, 2910 type-128mg (METHOCEL tMk4MCR)
Cross-linking sodium carboxymethyl cellulose-20mg ( )
Magnesium stearate-4mg
Method: mannitol, 71G, microcrystalline Cellulose, METHOCEL tMk4CR and be sieved through #20 order, and mix 10 minutes in a mixer.Magnesium stearate is sieved through #40 order, and joins blender, and mixes 5 minutes with lubrication mixture.Final mixture is pressed into 400-mg tablet weight, and the hardness between 8-15kp.
and METHOCEL tMthe compositions of (embodiment 4) is preferred preparation, because it provides the probability that relatively expands fast.Add super-disintegrant, such as secondary expansion probability.Different extension layer tablet weight in addition shown in embodiment 1 to 3 create extension layer identical needed for feature.
Embodiment 5
Mannitol-45mg
Microcrystalline Cellulose-25mg
CARBOPOL TM71G-64mg
Hydroxypropyl emthylcellulose, 2910 type-64mg (METHOCEL tMk4MCR)
Magnesium stearate-2mg
Method: mannitol, 71G, microcrystalline Cellulose and METHOCEL tMk4CR is sieved through #20 order, and mixes 10 minutes in a mixer.Magnesium stearate is sieved through #40 order, and joins blender, and mixes 5 minutes with lubrication mixture.Final mixture is pressed into 400-mg tablet weight, and the hardness between 8-15kp.
Embodiment 6
Extension layer tablet (embodiment 4)-370g
30D dispersion-300g
Calcium stearate powder-15g
Simethicone solid-0.15g
Pure water-85g
Method: the extension layer tablet will with 400mg Unit Weight loads conventional coating pan, and use conventional coating technology to incite somebody to action nE30D, dimeticone emulsion 30%, calcium stearate and pure water suspension spray, on extension layer tablet, produce barrier layer.By first dimeticone emulsion being joined pure water, and be mixed with suspension.Mix after about 10 minutes, add calcium stearate powder and mix.Mix after about 15 minutes, use suitable homogenizer with middling speed by calcium stearate suspension homogenize 10 minutes.In the different container, add aequum nE30D also mixes simultaneously, adds calcium stearate suspension.By final film coating suspension mixing about 20 minutes, be then sprayed on tablet.Then, the barrier layer tablet of coating processes 1-3 hour with stabilizing films at 60 DEG C.Then, the tablet of process is used for diffusion layer.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 2-10g/min.
Embodiment 7
Extension layer tablet (embodiment 4)-370g
nE30D dispersion-300g
Calcium stearate-15g
Dimeticone emulsion solid-0.15g
Pure water-85g
Method: the preparation of film coating suspension is identical with previous embodiment with the coating processing on barrier layer.In this embodiment, after barrier coating terminates, apply diffusion layer coating immediately, then at 60 DEG C, process tablet 1-3 hour.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 2-10g/min.
Embodiment 8
Extension layer tablet (embodiment 5)-400g
nE30D dispersion-150g
Calcium stearate-5g
Dimeticone emulsion solid-0.05g
Pure water-28g
Method: the extension layer tablet with 200mg Unit Weight is loaded conventional coating pan.Prepare similar to Example 6ly and contain the film coating suspension of NE30D, calcium stearate, dimeticone emulsion 30% suspension and pure water, and use conventional coating technology to sparge on extension layer tablet, produce barrier layer.The applicating adn implementing example 7 of barrier layer, diffusion layer and processing procedure is similar.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 2-10g/min.
Embodiment 9
Extension layer tablet (embodiment 3)-600g
nE30D dispersion-150g
Aerosil200-5g
Method: the extension layer tablet will with 600mg Unit Weight loads conventional coating pan, and use conventional coating technology to incite somebody to action nE30D, Aerosil200 and pure water suspension spray, on extension layer tablet, produce barrier layer.By Aerosil200 being joined aequum nE30D, and be mixed with film coating suspension.By final film coating suspension mixing about 20 minutes, be then sprayed on tablet.The applicating adn implementing example 7 and 8 of barrier layer, diffusion layer and processing procedure is similar.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 2-10g/min.
Embodiment 10
Extension layer tablet (embodiment 2)-400g
nE30D dispersion-150g
Talcum-15g
Pure water-50g
Method: the extension layer tablet will with 100mg Unit Weight loads conventional coating pan, and use conventional coating technology to incite somebody to action nE30D, Talcum and pure water dispersion are sprayed on extension layer tablet, produce barrier layer.By Talcum is mixed with the pure water of aequum, and mix, prepare barrier coating suspension.Mix after about 15 minutes, suspension was with middling speed homogenize 10 minutes.In different containers, add EUDRAGITNE30D.During mixing, add talc suspension, and the film coating suspension produced is mixed about 20 minutes, to be sprayed on tablet.The applicating adn implementing example 7 of barrier layer, diffusion layer and processing procedure, 8 similar with 9.Barrier layer is separated diffusion layer and extension layer, and also makes the resistance to crushing of tablet, resistance toly to smash to pieces and other physical methods of resistance to applying pressure.
Embodiment 11
Extension layer tablet (embodiment 4)-370g
nE30D dispersion-200g
rS30D dispersion-100g
Talcum-25g
Pure water-142g
Method: the extension layer tablet will with 400mg Unit Weight loads conventional coating pan, and use conventional coating technology to incite somebody to action nE30D, rS30D, Talcum and pure water suspension spray, in extension layer tablet, produce barrier layer.Film coating suspension preparation is closely similar with previous embodiment.Can pass through will rS30D polymer mixes barrier coating to be increased the impermeable feature of water of NE30D polymer.
Stop that the intensity of coated tablet and water impermeability characteristic dependence are in anticaking agents, such as Talcum, Aerosil200, calcium stearate, magnesium stearate and glyceryl monostearate.The stop coating of the dry of 5 – 95 % by weight that the starting weight based on extension layer tablet calculates provides relative compressive with water impervious tablet.Stop that the preferable range of coating is between 10-60 % by weight.If apply diffusion layer immediately after stop coating, then process together, then when broken, pulverize or crush time, stop coating and propagate polymerization thing coating are subsequently inseparable.
Embodiment 12
Stop coated tablet (embodiment 7)-475g
Oxycodone hydrochloride-37g
nE30D dispersion-175g
80-1.5g
200-2.0g
Pure water-100g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.By oxycodone hydrochloride, 80, 200 Hes the drug polymer coatings of NE30D suspension composition sparges and stops on coated tablet.By first will 80 pure water joining aequum, and mixing carrys out supending.Mixing continues about more than 10 minute.During mixing, will 200 powder join the suspension of previous steps, and mix about 1 minute.In different containers, add the EUDRAGITNE30D of aequum, and mix simultaneously, add oxycodone hydrochloride powder, and mixing continue about more than 15 minute to obtain uniform suspension.During mixing, add the suspension containing Tween-Aerosil, and by final suspension mixing about 20 minutes, be then sprayed on tablet.Then, the tablet of diffusion layer coating is processed 1-3 hour at 60 DEG C, with stable thin layer.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 13
Stop coated tablet (embodiment 7)-475g
Oxycodone hydrochloride-37g
nE30D dispersion-275g
Calcium stearate-6g
Dimeticone emulsion solid-0.06g
Pure water-34.4g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.By first dimeticone emulsion being joined pure water, and mixing carrys out supending.Mix after about 10 minutes, add calcium stearate powder and mix.Mix after about 15 minutes, use suitable homogenizer with middling speed by calcium stearate suspension homogenize 10 minutes.In different containers, add the EUDRAGITNE30D of aequum, and mix simultaneously, add oxycodone hydrochloride powder, and continue to mix about 15 minutes to obtain uniform suspension.In this uniform suspension, add calcium stearate suspension.By final film coating suspension mixing about 20 minutes, be then sprayed on tablet.Then, dispersion layer tablet is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 14
Stop coated tablet (embodiment 11)-485g
Oxycodone hydrochloride-74g
nE30D dispersion-350g
Tween80-2g
Calcium stearate-11g
Dimeticone emulsion solid-0.11g
Pure water-60g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.Will by oxycodone hydrochloride, the diffusion layer of NE30D, calcium stearate, dimeticone emulsion dispersion 30% and pure water suspension composition is sprayed to and stops on coated tablet.By first dimeticone emulsion being joined pure water, and mixing carrys out supending.Mix after about 10 minutes, add calcium stearate powder and mix.Mix after about 15 minutes, use suitable homogenizer with middling speed by calcium stearate suspension homogenize 10 minutes.In different containers, add the EUDRAGITNE30D of aequum, and mix simultaneously, add 80, and continue mixing about 10 minutes.After this, add oxycodone hydrochloride powder, and mix.Mix after about 15 minutes, add calcium stearate suspension.By final film coating suspension mixing about 20 minutes, be then sprayed on tablet.Then, dispersion layer tablet is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 15
Stop coated tablet (embodiment 8)-450g
Oxycodone hydrochloride-10g
nE30D dispersion-100g
Aerosil200-2g
Pure water-100g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.Will by oxycodone hydrochloride, nE30D, 200 and the diffusion layer of pure water dispersion composition be sprayed to and stop on coated tablet, then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.For the preparation of film coating suspension, reference example 12.
Embodiment 16
Stop coated tablet (embodiment 7)-475g
Synkonin-9.25g
nE30D dispersion-155g
200 powder-5g
-1.5g
Pure water-185g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.By first will 80 Hes 200 powder join pure water, and suspension mixing is prepared diffusion layer dispersion in about 10 minutes.Then, Synkonin powder is joined in suspension.By suspension mixing about 15 minutes, to realize being uniformly distributed of medicine.In different containers, add the EUDRAGITNE30D of aequum.During mixing, activity-Tween-Aerosil suspension is joined EUDRAGITNE30D dispersion, and mixing is not less than 20 minutes, is then sprayed to and stops on coated tablet.Then, the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 17
Stop coated tablet (embodiment 7)-475g
Morphine sulfate-55.6g
nE30D dispersion-275g
Aerosil200-5.0g
Pure water-150g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.Will by morphine sulfate, the diffusion layer of NE30D, Aerosil200 and pure water dispersion composition is sprayed to and stops on coated tablet, then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.By first will 200 powder join pure water, and suspension mixing is prepared diffusion layer dispersion in about 10 minutes.Then, morphine sulphate powder is joined suspension.Mixing, until obtain unit for uniform suspension.Suspension was with middling speed homogenize about 10 minutes.In different containers, add the EUDRAGITNE30D of aequum.During mixing, medicine-Aerosil suspension is joined EUDRAGITNE30D dispersion, and mixing is not less than 20 minutes, is then sprayed to and stops on coated tablet.
Embodiment 18
Stop coated tablet (embodiment 7)-475g
Dihydromorphinone hydrochloride-14.8g
nE30D dispersion-250g
200-5.0g
Pure water-100g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.Will by dihydromorphinone hydrochloride, nE30D, 200 and the diffusion layer of pure water dispersion composition be sprayed to and stop on coated tablet, then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.For the preparation of suspension, with reference to previous embodiment.
Embodiment 19
Stop coated tablet (embodiment 7)-475g
Oxymorphone hydrochloride-37g
nE30D dispersion-220g
80-2.5g
200-5.0g
Pure water-100g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by oxymorphone hydrochloride, nE30D, 80, be sprayed to the diffusion layer of pure water dispersion composition and stop on coated tablet.By first will 80 Hes 200 powder join pure water, and suspension mixing is prepared diffusion layer dispersion in about 10 minutes.Then, oxymorphone hydrochloride powder is joined suspension.Suspension is mixed about 15 minutes to obtain being uniformly distributed of medicine.In different containers, add the EUDRAGITNE30D of aequum.During mixing, activity-Tween-Aerosil suspension is joined EUDRAGITNE30D dispersion, and mixing is not less than 20 minutes, is then sprayed to and stops on coated tablet.Then, the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 20
Stop coated tablet (embodiment 8)-475g
Hydrochloric acid dexmethylphenidate-10g
nE30D dispersion-100g
Aerosil200-1g
Pure water-100g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by hydrochloric acid dexmethylphenidate, nE30D, 200 and the diffusion layer of pure water dispersion composition be sprayed to and stop on coated tablet, then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 21
Stop coated tablet (embodiment 10)-450g
Zaleplon-20g
nE30D dispersion-100g
200-1g
80-5g
Pure water-100g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by Zaleplon, nE30D, 200, 80 and the diffusion layer of pure water dispersion composition be sprayed to and stop on coated tablet.By first will 80 Hes 200 powder join pure water, and suspension mixing is prepared diffusion layer dispersion in about 10 minutes.Then, Zaleplon powder is joined in suspension.By suspension mixing about 15 minutes and homogenize 10 minutes, to realize being uniformly distributed of medicine.In different containers, add the EUDRAGITNE30D of aequum.During mixing, activity-Tween-Aerosil suspension is joined EUDRAGITNE30D dispersion, and mixing is not less than 20 minutes, is then sprayed to and stops on coated tablet.Then, the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 22
Stop coated tablet (embodiment 9)-695g
Propranolol hydrochloride-80g
nE30D dispersion-150g
200-5g
solution-1g
Pure water-100g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by propranolol hydrochloride, 200, 80, the diffusion layer of NE30D and pure water dispersion composition is sprayed to and stops on coated tablet, then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 23
Stop coated tablet (embodiment 6)-475g
Tramadol hydrochloride-92.6g
nE30D dispersion-290g
80-0.5g
200-5g
Pure water-250g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by tramadol hydrochloride, nE30D, 80, 200 and the diffusion layer of pure water dispersion composition be sprayed to and stop on coated tablet, then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 24 (drug product, conventional immediate release)
Stop coated tablet (embodiment 8)-450g
Oxycodone diffusion coating:
Oxycodone hydrochloride-10g
nE30D dispersion-100g
200-1g
Pure water-100g
Sub-coating, acetylamino benzophenone (Acetaminophenone) coating and sealing coating
Sub-coating-the 100g of 5%HPMC solution
Acetylamino benzophenone powder-2000g
10%HPMC solution-1000g
Pure water-1000g
5%HPMC seals coating-100g
Method: complete after stopping coating, oxycodone hydrochloride diffusion layer is applied in conventional coating pan immediately.Will by oxycodone hydrochloride, nE30D, 200 and the diffusion layer of pure water suspension composition be sprayed to and stop on coated tablet.Then the tablet of diffusion layer coating is processed 1-3 hour with stabilizing films at 60 DEG C.Once processing procedure completes, the sub-coating of application 5%HPMC, applies acetylamino benzophenone coating subsequently.Acetylamino benzophenone HPMC suspension is sprayed on tablet with 5-25g/min.By first 10%METHOCEL solution being mixed with the pure water of aequum, then active medicine being suspended, mixing simultaneously, prepare acetylamino benzophenone suspension.By suspension mixing about 15 minutes, then homogenize 10 minutes, was then sprayed on tablet.Alternatively, use powder feeder to be spread in coating pan by active agent powder, and use nozzle spray 10%HPMC solution.Keep the product temperature of about 30-35 DEG C.Once after applying all suspensions, application HPMC seals coating.Under product temperature between 38-40 DEG C, by tablet drying 5 minutes, then take out from coating pan.
Embodiment 25
Stop coated tablet-475g
diffusion layer coating:
Oxycodone hydrochloride-37g
nE30D dispersion-275g
80-2.5g
Calcium stearate-6g
Simethicone solid-0.06g
Pure water-34.4g
sustained release layer coating:
nE30D dispersion-30g
HPMC10% solution-30g
200-2.5g
Pure water-66g
Complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by oxycodone hydrochloride, nE30D, 80, the diffusion layer of calcium stearate, dimeticone emulsion 30% dispersion and pure water suspension composition is sprayed to and stops on coated tablet, subsequent spray sustained release film coating suspension.By inciting somebody to action nE30D, 10%HPMC solution, 200 and pure water mixing (about 15 minutes) prepare sustained release film coating suspension.After completing coating, then the tablet of coating processes 1-3 hour with stabilizing films at 60 DEG C.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 26
Diffusion layer tablet (embodiment 13)-600g
Opadry (Opadry) 85F18422 white powder-50g
Pure water-250g
After completing diffusion coating, color coating is applied to conventional coating pan immediately.By Opadry powder suspension is prepared color film coating suspension in pure water.About 300g color suspension is sprayed to diffusion layer coated tablet with the spray rate of 5-15g/min.In whole process, maintain the product temperature of 36-38 DEG C.
Embodiment 27
Stop coated tablet (embodiment 8)-450g
Oxycodone hydrochloride-10g
Morphine sulfate-20g
30D dispersion-125g
80-1.0g
200-2.0g
Pure water-100g
Method: complete after stopping coating, diffusion layer is applied in conventional coating pan immediately.Will by oxycodone hydrochloride, morphine sulfate, 80, 200 Hes the drug polymer coatings of NE30D suspension composition is sprayed to and stops on coated tablet.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
Embodiment 28
Stop coated tablet (embodiment 7)-475g
Oxycodone hydrochloride-9.3g
Morphine sulfate-18.5g
30D dispersion-275g
80-2.0g
200-2.5g
Pure water-100g
Method: complete after stopping coating, diffusion layer coating is applied in conventional coating pan immediately.Will by oxycodone hydrochloride, morphine sulfate, 80, 200 Hes the drug polymer coatings of NE30D suspension composition is sprayed to and stops on coated tablet.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
The anti-abuse capsule preparations of embodiment 29-
extension layer
barrier layer
diffusion layer
sustained release coating
color coating
Opadry 85Fl8422 powder-30mg
Pure water--------
Method: mannitol, microcrystalline Cellulose, 71G and METHOCEL tMk4MCR is selected by #20 mesh sieve, and mixes 10 minutes in a mixer.Magnesium stearate is selected by #40 mesh sieve, and joins in blender, and mixes 5 minutes with lubrication mixture.Final mixture is encapsulated in HPMC size #2 capsule with 300-mg weight package.Extension layer capsule loads conventional coating pan, and will nE30D, calcium stearate, dimeticone emulsion and pure water suspension spray, on capsule, produce barrier layer.Complete after stopping coating, diffusion layer is applied to conventional coating pan immediately, apply sustained release coating subsequently.Then, sustained release coated capsule processes 1-3 hour with stabilizing films at 60 DEG C.After processing procedure, application color coating.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.
The anti-abuse Bolus formulation of embodiment 30-
extension layer
barrier layer
diffusion layer
tablet formulation
AvicelPH102-100mg
AvicelPH200-100mg
Magnesium stearate-8mg
color coating
Opadry 85F18422 powder-30mg
Pure water--------
One or more active component can be placed in one or more single pill.In some embodiments, two or more dissimilar pills can use together, and wherein the pill of every type contains different active component.
Method: mannitol, microcrystalline Cellulose, 71G and METHOCEL tMk4MCR is selected by #20 mesh sieve, and is loaded into fluidized bed dryer/coating device that top-spray coating nozzle is housed.10%METHOCEL solution as binder solution spraying with by powder granulation.After completing required granulation, the humidity level of particle drying to about 2%.Dry granule takes out from fluid bed machine, and uses suitable milling machine, and such as specific dimensions made by Stokes oscillating granulator.Then, the dried particles with certain size is loaded into identical fluidized bed dryer/coating device, and will nE30D, rS30D, Talcum and pure water dispersion are sprayed to pill/granule, produce barrier layer.Complete after stopping coating, apply diffusion layer immediately.By oxycodone hydrochloride, nE30D, 200 and the diffusion layer of pure water suspension composition be sprayed to and stop on coated capsule, then the pill of diffusion layer coating is processed at 60 DEG C 1-3 hour with stabilizing films.In whole coating process, maintain the product temperature of 30-35 DEG C.The scope of spray rate is between 5-15g/min.Then, use suitable blender that the pill of process is mixed about 10 minutes with AvicelPH102 and AvicelPH200.Magnesium stearate is joined blender, and mixes 5 minutes.Final mixture is pressed into the hardness of 766mg tablet weight and 8-16kp.Then, the tablet of compacting is loaded into conventional coating pan, for color coating.
Embodiment 31
extension layer
barrier layer
diffusion layer
color coating
Opadry 85F18422 powder-30mg
Pure water---------
When suitably (complete) take to take with the ground form of same piece agent formulation compared with time, the rate of release of the tablet prepared according to embodiment 31 by contrast, tests this preparation about oxycodone.Result is reported in Fig. 1, and display is when tablet is suitably taken, and most drug is discharged in patient.
The tablet comprising the pharmaceutical composition of embodiment 31 uses sharp equipment, and such as cutter and shears are cut into 2 and 8.Extension layer powder is completely removed.Fig. 4 shows the contrast of this speed.This confirms when tablet of the present invention is by physical damage, and the secondary or physical bond between diffusion layer and barrier layer is retained substantially.The relative surface area of diffusion layer only increases on edge, prevents the remarkable increase of drug release.Therefore, in some embodiments, even when the dosage form containing pharmaceutical composition of the present invention is by physical damage, contrast with complete dosage form, medicine keeps identical release characteristic substantially.

Claims (38)

1. a combination of oral medication, it comprises: the barrier layer comprising the first polymer; With the diffusion layer comprising the second polymer and substantially cover described barrier layer, wherein said diffusion layer is incorporated into described barrier layer, and comprises and being evenly distributed in very much in described second polymer and the medicine spread from described diffusion layer in gastrointestinal (GI) road.
2. pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition comprises extension layer further, and described extension layer comprises easily extensible polymer, and wherein said barrier layer covers described extension layer substantially.
3. pharmaceutical composition as claimed in claim 2, wherein said extension layer comprises the polymer existed with the weight range of 5% to 90% of the gross weight of described dosage form.
4. pharmaceutical composition as claimed in claim 2 or claim 3, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is by physical damage, and when the granule of the described pharmaceutical composition containing described extension layer is formed and is exposed to liquid, the easily extensible polymer of described easily extensible layer at least absorbs a part of described liquid.
5. the pharmaceutical composition as described in any one in claim 1-4, wherein said diffusion layer by physical bond in described barrier layer.
6. the pharmaceutical composition as described in any one in claim 1-5, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is used with complete form, first polymer on described barrier layer is substantially insoluble in the gastrointestinal tract.
7. the pharmaceutical composition as described in any one in claim 1-6, time-releasable medications in the time that the second polymer of wherein said diffusion layer is provided in about 6 to about 24 hours.
8. the pharmaceutical composition as described in any one in claim 1-7, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is by physical damage, and when forming the granule of the described pharmaceutical composition containing described diffusion layer and described barrier layer, the described diffusion layer in described granule and the key between barrier layer are retained substantially.
9. the pharmaceutical composition as described in any one in claim 1-8, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with physically destroyed form, be selected from use after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours with a period of time of the group of 48 hours compositions after Cmax and/or AUC that realize identical with Cmax and/or AUC realized when using described pharmaceutical composition with complete form, or lower than it.
10. pharmaceutical composition as claimed in claim 9, wherein said pharmaceutical composition is formulated, thus be selected from use after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours and 48 hours compositions group a period of time after Cmax and/or the AUC 20-75% lower than Cmax and/or AUC realized when described pharmaceutical composition is applied to curee with complete form that realize.
11. pharmaceutical compositions as described in any one in claim 1-10, wherein said pharmaceutical composition comprises other releasing layer, other releasing layer wherein said is the basic release layer covering described diffusion layer, and other releasing layer wherein said comprises other medicine of at least one.
12. pharmaceutical compositions as claimed in claim 11, other medicine of the described at least one wherein in other releasing layer described is selected from the group be made up of acetaminophen and NSAID (non-steroidal anti-inflammatory drug).
13. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with physically destroyed form, the Cmax/AUC using rear realization is lower than the Cmax/AUC realized after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours and a period of time of group of forming for 48 hours after being selected from the bioequivalence compositions using the physical damage not comprising anti-abuse methods.
14. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with physically destroyed form, Cmax and/or AUC using rear realization is lower than Cmax and/or AUC realized after 2 hours, 4 hours, 8 hours, 12 hours, 24 hours and a period of time of group of forming for 48 hours after being selected from the bioequivalence compositions used and do not comprise anti-abuse methods.
15. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with the form be physically destroyed, be substantially equal to or less than drug release rate when described pharmaceutical composition is used with complete form by medicine in 2 hours, 4 hours, 8 hours and a period of time of group of forming for 16 hours from the speed that described compositions discharges being selected from.
16. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with the form be physically destroyed, be substantially equal to or less than release amount of medicine when described pharmaceutical composition is used with complete form by medicine in 2 hours, 4 hours, 8 hours and a period of time of group of forming for 16 hours from the amount that described compositions discharges being selected from.
17. pharmaceutical compositions as claimed in claim 16, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with the form be physically destroyed, be no more than 75% of the release amount of medicine when described pharmaceutical composition is used with complete form by medicine in 2 hours, 4 hours, 8 hours and a period of time of group of forming for 16 hours from the amount that described compositions discharges being selected from.
18. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition thereof wine or when taking together with wine, be selected from by 2 hours, 4 hours, 8 hours within a period of time of the group to form for 16 hours medicine to be substantially equal to or less than the speed of the drug release when described pharmaceutical composition is not used together with wine from the speed that described compositions discharges.
19. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is used with complete form, after 8 hours, the medicine of the amount of at least 50% is released, and when described pharmaceutical composition is used with physically destroyed form, after 1 hour, the medicine being no more than the amount of 40% is released.
20. pharmaceutical compositions as claimed in claim 19, wherein when described pharmaceutical composition is used with physically destroyed form, after 15 minutes, the medicine being no more than the amount of 35% is released.
21. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is used with complete form, after 1 hour, the medicine of the amount of at least 90% is released, and when described pharmaceutical composition is used with physically destroyed form, after 1 hour, the medicine being no more than the amount of 75% is released.
22. pharmaceutical compositions as described in any one in claim 1-21, wherein said pharmaceutical composition exists with pharmaceutical dosage form, and described pharmaceutical dosage form is selected from the group be made up of tablet, capsule, microplate, granule, pill, lozenge, lollipop and coated capsule.
23. pharmaceutical compositions as claimed in claim 22, wherein said pharmaceutical dosage form is tablet.
24. pharmaceutical compositions as described in any one in claim 1-23, wherein said medicine is selected from the group be made up of central nervous system stimulant and central nervous system depressant.
25. pharmaceutical compositions as described in any one in claim 1-23, are wherein saidly selected from the group be made up of OPIOIDS class, barbiturates, Benzodiazepines and amphetamine-type.
26. pharmaceutical compositions as claimed in claim 25, wherein said medicine is selected from the OPIOIDS by the following group formed: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, Clonitazene, codeine, Desomorphine, dextromoramide, dezocine, diampromide, diamorphine, dihydrocodeine, paramorphan (dihydromorphine), dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, Pethidine, meptazinol, metazocine, methadone, metopon, morphine, Myrophine, papaverine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, pirinitramide, propheptazine, Promedol, properidine, dextropropoxyphene, sufentanil, tilidate, tramadol and pharmaceutically acceptable salt thereof.
27. pharmaceutical compositions as claimed in claim 26, wherein said OPIOIDS is oxycodone or its pharmaceutically acceptable salt, and it exists with the amount of about 5mg to about 400mg.
28. pharmaceutical compositions as claimed in claim 26, wherein said OPIOIDS is morphine or its pharmaceutically acceptable salt, and it exists with the amount of about 15mg to about 800mg.
29. pharmaceutical compositions as claimed in claim 26, wherein said OPIOIDS is hydromorphone or its pharmaceutically acceptable salt, and it exists with the amount of about 1mg to about 64mg.
30. pharmaceutical compositions as claimed in claim 26, wherein said OPIOIDS is hydrocodone or its pharmaceutically acceptable salt, and it exists with the amount of about 5mg to about 400mg.
31. pharmaceutical compositions as claimed in claim 26, wherein said OPIOIDS is oxymorphone or its pharmaceutically acceptable salt, and it exists with the amount of about 4mg to about 80mg.
32. 1 kinds of methods preparing anti-abuse combination of oral medication, it comprises: form barrier layer, wherein said barrier layer comprises the first polymer; And diffusion layer being applied to substantially to cover described barrier layer on described barrier layer, wherein said diffusion layer comprises the second polymer and is evenly distributed on the medicine in described second polymer; And described diffusion layer is incorporated into described barrier layer.
33. methods as claimed in claim 32, the combination of wherein said diffusion layer to described barrier layer is physical bond.
34. 1 kinds of methods preparing anti-abuse combination of oral medication, it comprises: form the extension layer comprising easily extensible polymer; By barrier application on described extension layer substantially to cover described extension layer, wherein said barrier layer comprises the first polymer; Be applied to by diffusion layer substantially to cover described barrier layer on described barrier layer, wherein said diffusion layer comprises the second polymer and is evenly distributed on the medicine in described second polymer; And described diffusion layer is incorporated into described barrier layer.
35. methods as claimed in claim 34, the combination of wherein said diffusion layer to described barrier layer is physical bond.
36. methods as described in claim 34 or 35, it is comprised and being applied on described extension layer by spraying or dry coating on described barrier layer.
37. 1 kinds of methods for the treatment of illness, it comprises the pharmaceutical composition using in claim 1-31 described in any one to its patient of needs.
38. 1 kinds of combination of oral medication, it comprises the medicine of pharmaceutical effective amount, wherein said pharmaceutical composition is formulated, so that when described pharmaceutical composition is applied to curee with physically destroyed form, the intensity of the excitement that excited intensity realizes after being substantially equal to or less than the physically destroyed bioequivalent compositions of the method used not containing anti-abuse.
CN201510883951.2A 2007-08-13 2008-08-12 Abuse resistant drugs, methods of use and methods of preparation Active CN105534936B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95558407P 2007-08-13 2007-08-13
US60/955,584 2007-08-13
CN200880103447A CN101801350A (en) 2007-08-13 2008-08-12 Abuse resistant drugs, using method and preparation method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880103447A Division CN101801350A (en) 2007-08-13 2008-08-12 Abuse resistant drugs, using method and preparation method

Publications (2)

Publication Number Publication Date
CN105534936A true CN105534936A (en) 2016-05-04
CN105534936B CN105534936B (en) 2020-07-31

Family

ID=40351440

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880103447A Pending CN101801350A (en) 2007-08-13 2008-08-12 Abuse resistant drugs, using method and preparation method
CN201510883951.2A Active CN105534936B (en) 2007-08-13 2008-08-12 Abuse resistant drugs, methods of use and methods of preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200880103447A Pending CN101801350A (en) 2007-08-13 2008-08-12 Abuse resistant drugs, using method and preparation method

Country Status (11)

Country Link
US (23) US10736850B2 (en)
EP (1) EP2187873B1 (en)
JP (2) JP5965583B2 (en)
CN (2) CN101801350A (en)
AU (4) AU2008286914B2 (en)
BR (1) BRPI0815387B8 (en)
CA (2) CA2923102C (en)
ES (1) ES2692437T3 (en)
MX (1) MX336789B (en)
PL (1) PL2187873T3 (en)
WO (1) WO2009023672A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
CA2923102C (en) * 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009282376A1 (en) * 2008-08-12 2010-02-18 Inspirion Delivery Technologies, Llc Pharmaceutical compositions configured to deter dosage form splitting
WO2010069050A1 (en) * 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
US20110311631A1 (en) * 2009-03-18 2011-12-22 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
WO2017099974A1 (en) * 2015-10-20 2017-06-15 Jun Xia Systems for brain stimulation during sleep and methods of use thereof
FR2979242A1 (en) * 2011-08-29 2013-03-01 Sanofi Sa COMPRESSES AGAINST ABUSIVE USE, BASED ON PARACETAMOL AND OXYCODONE
ES2583132T3 (en) * 2011-09-16 2016-09-19 Purdue Pharma L.P. Immediate release formulations resistant to alteration
MX356111B (en) 2012-04-18 2018-05-15 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions.
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX2015013231A (en) 2013-03-15 2016-06-07 Inspirion Delivery Technologies Llc Abuse deterrent compositions and methods of use.
CA2906915A1 (en) 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
ES2681952T3 (en) 2013-03-15 2018-09-17 SpecGx LLC Solid pharmaceutical form deterrent of immediate release abuse with functional score
US20150005334A1 (en) * 2013-03-15 2015-01-01 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド Extruded immediate release abuse deterrent pills
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015066172A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9649279B2 (en) * 2013-12-16 2017-05-16 Massachusetts Institute Of Technology Fortified micronutrient salt formulations
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR101471361B1 (en) * 2014-03-18 2014-12-11 (주)앤디포스 Double-sided tape for touch screen panel and manufacturing method thereof
PT3164117T (en) 2014-07-03 2023-12-12 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
ES2809458T3 (en) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Liquid filled, abuse deterrent and immediate release dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
EP3193873A4 (en) * 2014-09-15 2018-05-30 Inspirion Delivery Technologies, LLC Orally administrable compositions and methods of deterring abuse by intranasal administration
US20160078189A1 (en) * 2014-09-16 2016-03-17 Scott Laboratories, Inc. Sedation system and method providing enhanced safety
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
JP6131379B1 (en) * 2016-12-28 2017-05-17 森下仁丹株式会社 Formulation containing 4,5-epoxymorphinan derivative
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326339A (en) * 1998-11-11 2001-12-12 法马西雅公司 Controlled release bead, method of producing the same and multiple unit formulation comprising it
CN1863513A (en) * 2003-08-06 2006-11-15 格吕伦塔尔有限公司 Abuse-proffed dosage form
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US72914A (en) * 1867-12-31 Improvement in locks for travelling-bags
US70237A (en) * 1867-10-29 James d
DE2224160C3 (en) * 1972-05-18 1979-10-04 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Process for the production of catalysts for the production of pyridine and 3-methylpyridine
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (en) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgesic drugs with reduced potential for abuse
DD146547A5 (en) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim MEDICINAL RETARDANT SHAPE WITH UNFORGETTABLE POROESEN DIFFUSION SHELLS
US4423099A (en) 1980-07-28 1983-12-27 Ciba-Geigy Corporation Membrane modified hydrogels
IT1153487B (en) 1982-04-15 1987-01-14 Prophin Lab Spa PHARMACEUTICAL PRODUCTS IN FORM-DELAY AND PROCEDURE TO OBTAIN THEM
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
IT1201136B (en) 1987-01-13 1989-01-27 Resa Farma TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF SUBSTANCES OF ACTIVE SUBSTANCES
FI101344B1 (en) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Process for the preparation of a composition for controlled release of a pharmaceutically active substance
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US5206030A (en) * 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
SE9301057L (en) 1993-03-30 1994-10-01 Pharmacia Ab Controlled release preparation
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
AT403988B (en) 1994-05-18 1998-07-27 Lannacher Heilmittel SOLID ORAL RETARDED PREPARATION
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5645858A (en) 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282576B1 (en) * 1996-02-06 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES
DE19630035A1 (en) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol multiple unit formulations
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
AU773642C (en) * 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6309608B1 (en) * 1998-04-23 2001-10-30 Stephen Matson Method and apparatus for organic synthesis
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
MXPA01006108A (en) 1998-12-17 2002-09-18 Alza Corp Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
FR2787715B1 (en) * 1998-12-23 2002-05-10 Synthelabo PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
PT2092936E (en) 2000-02-08 2013-06-20 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
AR030557A1 (en) * 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
WO2003004032A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
DE20220910U1 (en) * 2001-08-06 2004-08-05 Euro-Celtique S.A. Anti-abuse compositions for opioids
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
EP1429728A1 (en) 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
EP1438028A1 (en) 2001-09-28 2004-07-21 McNEIL-PPC, INC. Modified release dosage forms
GB0126064D0 (en) * 2001-10-30 2001-12-19 Reckitt Benckiser Healthcare Improvements in or relating to organic compositions
US20030125714A1 (en) * 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
CA2473991C (en) 2002-02-01 2009-09-15 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
EP2319540A1 (en) * 2002-02-22 2011-05-11 Shire LLC Sustained release pharmaceutical compounds to prevent abuse of controlled substances
DE10208335A1 (en) * 2002-02-27 2003-09-04 Roehm Gmbh Pharmaceutical form and process for its preparation
WO2003082207A2 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
CN102813654A (en) * 2002-04-05 2012-12-12 欧洲凯尔蒂克公司 Matrix for sustained, invariant and independent release of active compounds
JP4133019B2 (en) * 2002-06-21 2008-08-13 日産ディーゼル工業株式会社 Power storage control device for vehicle
JP4694207B2 (en) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル, インコーポレイテッド Abuse deterrent pharmaceutical compositions for opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
SI1894562T1 (en) 2002-08-15 2011-04-29 Euro Celtique Sa Pharmaceutical compositions comprising an opioid antagonist
ES2677769T3 (en) * 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and procedures
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
DE10250543A1 (en) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Multilayer dosage form
ES2553136T3 (en) * 2002-12-13 2015-12-04 Durect Corporation Oral drug delivery system comprising high viscosity liquid vehicle materials
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
JP2004320263A (en) * 2003-04-14 2004-11-11 Nikon Corp Image reading device, program, and image reading method
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
KR101159477B1 (en) * 2003-05-29 2012-07-02 샤이어 엘엘씨 Abuse resistant amphetamine compounds
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
CA2536816A1 (en) * 2003-08-12 2005-03-03 Endo Pharmaceuticals, Inc. Method for deterring abuse of opioids by combination with non-release formulation of emetic
WO2005030181A1 (en) 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
EA008864B1 (en) * 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Pharmaceutical compositions for of overdose or abuse
US20050074493A1 (en) 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
US7494028B2 (en) * 2003-10-15 2009-02-24 Zavida Coffee Company Inc. Fluid dispensing system suitable for dispensing liquid flavorings
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE602004005076T2 (en) * 2003-12-09 2007-11-15 Euro-Celtique S.A. CO-EXTRUDED SAFETY DOSAGE FORM WITH AN ACTIVE AGENT AND AN ADVERSE AGENT AND METHOD OF MANUFACTURING THEREOF
EP1763337A2 (en) 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US20050163843A1 (en) 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
NZ549838A (en) 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
WO2005094821A1 (en) * 2004-03-30 2005-10-13 Lotus Pharmaceutical Co.,Ltd. A medical composition for increasing the medicine safety
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
EP3326617A1 (en) * 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
GB2419838A (en) * 2004-11-03 2006-05-10 Reckitt Benckiser Nv Making a tablet of three layers
AR051950A1 (en) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent MULTI-PAD COMPRESSED WITH SEPARATING LAYERS
US7205385B2 (en) * 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP2319499A1 (en) * 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
US20060189635A1 (en) 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
US7424221B2 (en) * 2005-03-04 2008-09-09 Tellabs Petaluma, Inc. Optical network terminal with illegal transmission detection circuitry
IS7748A (en) 2005-03-17 2006-09-18 Actavis Group Composition for tablets containing topiramate
WO2006102964A2 (en) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
PE20070325A1 (en) * 2005-06-29 2007-05-12 Alza Corp ORAL DOSAGE FORMS THAT INCLUDE CARBAMATE-DERIVED COMPOUNDS
WO2007013975A2 (en) * 2005-07-20 2007-02-01 Pharmorx Inc. Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
DK1931346T3 (en) * 2005-09-09 2012-10-22 Angelini Labopharm Llc Trazodone composition for once daily administration
GB0612326D0 (en) 2005-10-31 2006-08-02 Alza Corp Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US9522188B2 (en) * 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
JP2009523833A (en) * 2006-01-21 2009-06-25 アボット ゲーエムベーハー ウント カンパニー カーゲー Formulations and methods for drug delivery
EP1976491B1 (en) * 2006-01-27 2014-12-17 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
DK2428205T3 (en) 2006-03-16 2012-10-22 Tris Pharma Inc MODIFIED FORMULATIONS CONTAINING PHARMACEUTICAL ION EXCHANGE RESIN COMPLEX
KR20090029710A (en) * 2006-05-02 2009-03-23 파나세아 바이오테크 리미티드 Transmucosal composition
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
AU2007275034A1 (en) 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008027293A2 (en) * 2006-08-25 2008-03-06 Emphasys Medical, Inc. Bronchial isolation devices for placement in short lumens
ES2547226T5 (en) 2006-08-30 2020-06-12 Jagotec Ag Oral controlled release dosage formulations comprising a core and one or more barrier layers
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
DE102006051020A1 (en) 2006-10-26 2008-04-30 Evonik Röhm Gmbh Use of enteric (meth)acrylate copolymers in controlled-release oral pharmaceutical dosage forms as drug matrix formers to reduce the effect of ethanol-induced release rate increase or decrease in vitro
EP2155167A2 (en) * 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
CA2923102C (en) * 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
WO2009036812A1 (en) 2007-09-21 2009-03-26 Evonik Röhm Gmbh Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
WO2009036811A1 (en) * 2007-09-21 2009-03-26 Evonik Röhm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
TW200950776A (en) 2008-01-24 2009-12-16 Abbott Gmbh & Co Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
CA2741701A1 (en) 2008-10-31 2010-05-06 Mcneil-Ppc, Inc. Osmotic tablet with a compressed outer coating
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CA2906172C (en) * 2013-03-15 2021-12-21 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of topiramate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326339A (en) * 1998-11-11 2001-12-12 法马西雅公司 Controlled release bead, method of producing the same and multiple unit formulation comprising it
CN1863513A (en) * 2003-08-06 2006-11-15 格吕伦塔尔有限公司 Abuse-proffed dosage form
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王军: "与阿片制剂成瘾相关的中枢神经递质及其机制研究进展", 《中风与神经疾病杂志》 *

Also Published As

Publication number Publication date
CN105534936B (en) 2020-07-31
US10729656B2 (en) 2020-08-04
CA2696341C (en) 2016-05-17
US20140248343A1 (en) 2014-09-04
US20150044282A1 (en) 2015-02-12
AU2008286914A1 (en) 2009-02-19
US20110150991A1 (en) 2011-06-23
US20110150969A1 (en) 2011-06-23
US20120156277A1 (en) 2012-06-21
WO2009023672A2 (en) 2009-02-19
EP2187873A4 (en) 2013-09-04
BRPI0815387B8 (en) 2021-05-25
US11291634B2 (en) 2022-04-05
JP2016138126A (en) 2016-08-04
US10736851B2 (en) 2020-08-11
BRPI0815387B1 (en) 2020-08-11
PL2187873T3 (en) 2019-01-31
CA2923102C (en) 2019-10-15
US10688055B2 (en) 2020-06-23
AU2015200009A1 (en) 2015-01-29
ES2692437T3 (en) 2018-12-03
US10688054B2 (en) 2020-06-23
US20110159089A1 (en) 2011-06-30
US20120164209A1 (en) 2012-06-28
US7955619B2 (en) 2011-06-07
WO2009023672A3 (en) 2009-12-30
US10736852B2 (en) 2020-08-11
US10695298B2 (en) 2020-06-30
US20140377352A1 (en) 2014-12-25
US20150064247A1 (en) 2015-03-05
CA2923102A1 (en) 2009-02-19
AU2008286914B2 (en) 2014-10-02
US20110150971A1 (en) 2011-06-23
US20110002985A1 (en) 2011-01-06
JP5965583B2 (en) 2016-08-10
US20110150970A1 (en) 2011-06-23
US10314788B2 (en) 2019-06-11
US10688053B2 (en) 2020-06-23
US10729657B2 (en) 2020-08-04
US11285112B2 (en) 2022-03-29
US11045422B2 (en) 2021-06-29
US20150071995A1 (en) 2015-03-12
US10688051B2 (en) 2020-06-23
US10736850B2 (en) 2020-08-11
CN101801350A (en) 2010-08-11
AU2019200895A1 (en) 2019-02-28
US20110150990A1 (en) 2011-06-23
CA2696341A1 (en) 2009-02-19
US20150071998A1 (en) 2015-03-12
US20110184007A1 (en) 2011-07-28
US20150064248A1 (en) 2015-03-05
US20110076325A1 (en) 2011-03-31
JP2010536770A (en) 2010-12-02
US11191730B2 (en) 2021-12-07
US20140248344A1 (en) 2014-09-04
MX336789B (en) 2016-02-02
US20110159090A1 (en) 2011-06-30
BRPI0815387A2 (en) 2017-05-23
US10702480B2 (en) 2020-07-07
US11278500B2 (en) 2022-03-22
EP2187873B1 (en) 2018-07-25
EP2187873A2 (en) 2010-05-26
MX2010001812A (en) 2010-08-04
JP6608319B2 (en) 2019-11-20
US20190209480A1 (en) 2019-07-11
US10688052B2 (en) 2020-06-23
AU2017200414A1 (en) 2017-02-09
US20150064245A1 (en) 2015-03-05
US20150064246A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
CN105534936A (en) Abuse resistant drugs, method of use and method of making

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200629

Address after: Podolico hongkos

Applicant after: Ohemo Life Sciences Co.,Ltd.

Address before: New jersey, USA

Applicant before: Insperrun Transportation Science Co.,Ltd.

Effective date of registration: 20200629

Address after: New jersey, USA

Applicant after: Insperrun Transportation Science Co.,Ltd.

Address before: New York State, USA

Applicant before: Insperion Transportation Technology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant